Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Melanoma-Pipeline Review, H1 2015

Metastatic Melanoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Melanoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Melanoma-Pipeline Review, H1 2015', provides an overview of the Metastatic Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Metastatic Melanoma Overview 12

Therapeutics Development 13

Pipeline Products for Metastatic Melanoma-Overview 13

Pipeline Products for Metastatic Melanoma-Comparative Analysis 14

Metastatic Melanoma-Therapeutics under Development by Companies 15

Metastatic Melanoma-Therapeutics under Investigation by Universities/Institutes 22

Metastatic Melanoma-Pipeline Products Glance 24

Late Stage Products 24

Clinical Stage Products 25

Early Stage Products 26

Metastatic Melanoma-Products under Development by Companies 27

Metastatic Melanoma-Products under Investigation by Universities/Institutes 35

Metastatic Melanoma-Companies Involved in Therapeutics Development 36

AB Science 36

AbbVie Inc. 37

Adaptimmune Limited 38

Affichem 39

Agalimmune Ltd 40

Agenus, Inc. 41

Altor BioScience Corporation 42

Amgen Inc. 43

Astex Pharmaceuticals, Inc. 44

AstraZeneca PLC 45

AVAX Technologies, Inc. 46

Bayer AG 47

Bioncotech Therapeutics S.L. 48

Bionomics Limited 49

Boehringer Ingelheim GmbH 50

Bristol-Myers Squibb Company 51

Cancer Therapeutics CRC Pty Ltd 52

Cavion LLC 53

Celgene Corporation 54

Celldex Therapeutics, Inc. 55

Colby Pharmaceutical Company 56

CureTech Ltd. 57

Delcath Systems, Inc. 58

Digna Biotech, S.L. 59

DNA Therapeutics S.A. 60

Eisai Co., Ltd. 61

Eli Lilly and Company 62

F. Hoffmann-La Roche Ltd. 63

Galapagos NV 64

Galectin Therapeutics, Inc. 65

GlaxoSmithKline plc 66

HanAll Biopharma Co., Ltd. 67

Immune Design Corp. 68

Immunophotonics Inc 69

ImmuRx, Inc. 70

Incyte Corporation 71

Life Science Pharmaceuticals, Incorporated 72

Lipotek Pty Ltd. 73

Luitpold Pharmaceuticals, Inc. 74

MedImmune, LLC 75

Merck & Co., Inc. 76

Merck KGaA 77

Momenta Pharmaceuticals, Inc. 78

Morphotek, Inc. 79

NeoStem, Inc. 80

NewLink Genetics Corporation 81

Novartis AG 82

Omeros Corporation 83

Oncolytics Biotech Inc. 84

OncoSec Medical Inc. 85

Ono Pharmaceutical Co., Ltd. 86

Onxeo SA 87

Pfizer Inc. 88

Philogen S.p.A. 89

Plexxikon Inc. 90

Polyphor Ltd. 91

Provectus Biopharmaceuticals, Inc. 92

Provenance Biopharmaceuticals Corp. 93

Reata Pharmaceuticals, Inc. 94

Recombio S.L 95

Sanofi 96

SBI Biotech Co., Ltd. 97

Scancell Holdings Plc 98

Takara Bio Inc. 99

Takeda Oncology 100

Ultimovacs AS 101

Vaxeal Holding SA 102

Vical Incorporated 103

WntResearch AB 104

ZIOPHARM Oncology, Inc. 105

Metastatic Melanoma-Therapeutics Assessment 106

Assessment by Monotherapy Products 106

Assessment by Combination Products 107

Assessment by Target 108

Assessment by Mechanism of Action 115

Assessment by Route of Administration 120

Assessment by Molecule Type 122

Drug Profiles 124

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 124

4-Peptide Melanoma Vaccine-Drug Profile 126

A-dmDT390-bisFv-Drug Profile 127

Ad-RTS-IL-12-Drug Profile 128

AF-122-Drug Profile 130

ALT-801-Drug Profile 131

ALT-803-Drug Profile 133

AMG-232-Drug Profile 135

Anti-CSPG4-IL2-Drug Profile 136

austrasulfone-Drug Profile 137

axitinib-Drug Profile 138

BA-015-Drug Profile 141

bevacizumab-Drug Profile 143

BGJ-398-Drug Profile 148

binimetinib + encorafenib-Drug Profile 149

BL-011256-Drug Profile 151

BNC-420-Drug Profile 152

BO-110-Drug Profile 153

buparlisib hydrochloride-Drug Profile 154

Cancer Stem Cell Therapy-Drug Profile 158

capmatinib-Drug Profile 159

Cell Therapy to Target HERV-K for Metastatic Melanoma-Drug Profile 161

Cell Therapy to Target Melanoma Antigen Recognized By T-Cells 1 for Metastatic Melanoma-Drug Profile 162

Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology-Drug Profile 163

Cell Therapy to Target NY-ESO-1 for Metastatic Melanoma-Drug Profile 165

Cell Therapy to Target NY-ESO-1 for Oncology-Drug Profile 166

cobimetinib-Drug Profile 167

contego-Drug Profile 171

CPC-410-Drug Profile 173

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide-Drug Profile 174

Darleukin-Drug Profile 175

DB-039-Drug Profile 177

Dendritic Cell Therapy 2 for Metastatic Melanoma-Drug Profile 178

Dendritic Cell Therapy for Metastatic Melanoma-Drug Profile 179

Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma-Drug Profile 180

Dendritic Cell Therapy to Target gp100, Melan-A, MAGEA3 and Tyrosinase for Metastatic Melanoma-Drug Profile 181

Dendritic Cell Therapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma-Drug Profile 182

DNA IL-12-Drug Profile 183

DT-01-Drug Profile 185

E-6201-Drug Profile 187

ecromeximab-Drug Profile 189

eltrapuldencel-T-Drug Profile 190

encorafenib-Drug Profile 192

G-305-Drug Profile 194

glembatumumab vedotin-Drug Profile 195

GLPG-1790-Drug Profile 197

GR-MD-02-Drug Profile 198

GSK-2132231A-Drug Profile 200

GSK-2241658A-Drug Profile 201

GSK-2302025A-Drug Profile 202

HF-10-Drug Profile 203

HL-156CAN-Drug Profile 204

HL-176-Drug Profile 205

HL-177-Drug Profile 206

ICOVIR-5-Drug Profile 207

INCB-24360-Drug Profile 208

inCVAX-Drug Profile 210

indoximod-Drug Profile 212

ipilimumab-Drug Profile 214

lenvatinib-Drug Profile 218

Lipovaxin-MM-Drug Profile 222

LOC-paclitaxel-Drug Profile 223

LV-305-Drug Profile 224

LY-3009120-Drug Profile 225

M-200-Drug Profile 226

M-Vax-Drug Profile 227

masitinib-Drug Profile 229

melphalan-Drug Profile 232

MelVax-Drug Profile 234

mibefradil dihydrochloride-Drug Profile 235

miRNA-7-5p-Drug Profile 237

MLN-2480-Drug Profile 238

Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma-Drug Profile 240

MORAb-050-Drug Profile 241

MSX-122-Drug Profile 242

NAcGM3/VSSP Vaccine-Drug Profile 244

necuparanib-Drug Profile 246

nilotinib-Drug Profile 247

nintedanib-Drug Profile 250

nivolumab (recombinant)-Drug Profile 254

onalespib-Drug Profile 259

ontuxizumab-Drug Profile 262

paclitaxel albumin bound-Drug Profile 264

palbociclib-Drug Profile 268

pasireotide-Drug Profile 272

pelareorep-Drug Profile 275

pembrolizumab-Drug Profile 280

pevonedistat hydrochloride-Drug Profile 284

pidilizumab-Drug Profile 286

pimasertib hydrochloride-Drug Profile 288

PLX-3397-Drug Profile 290

POL-7085-Drug Profile 292

PV-10-Drug Profile 293

Q-204-Drug Profile 296

RAF-265-Drug Profile 297

Recombinant Protein for Metastatic Melanoma-Drug Profile 298

Recombinant Protein for Oncology-Drug Profile 299

RG-7446-Drug Profile 300

Riluzole Prodrugs-Drug Profile 302

RTA-408-Drug Profile 303

SAGEs for Cancer-Drug Profile 306

sagopilone-Drug Profile 307

SAR-260301-Drug Profile 309

SCIB-1-Drug Profile 310

selumetinib sulfate-Drug Profile 313

Small Molecule to Antagonize GPR19 for Metastatic Melanoma-Drug Profile 316

Small Molecules to Antagonize ET-B for Oncology-Drug Profile 317

Small Molecules to Inhibit FAK-FLT3-VEGFR3 for Oncology-Drug Profile 318

sunitinib malate-Drug Profile 319

SVX-1-Drug Profile 323

Synthetic Peptide for Malignant Melanoma-Drug Profile 324

TAK-733-Drug Profile 325

talimogene laherparepvec-Drug Profile 327

TMECG-Drug Profile 330

TPI-287-Drug Profile 331

tremelimumab + MEDI-3617-Drug Profile 333

UV-1-Drug Profile 334

Vaccine for Cancer-Drug Profile 335

Vaccine for Metastatic Melanoma-Drug Profile 336

Vaccine For Oncolytic Newcastle Disease Virus-Drug Profile 337

varlilumab-Drug Profile 338

velimogene aliplasmid-Drug Profile 340

veliparib-Drug Profile 343

vemurafenib-Drug Profile 346

ZSG-101-Drug Profile 349

ZSG-102-Drug Profile 350

Metastatic Melanoma-Recent Pipeline Updates 351

Metastatic Melanoma-Dormant Projects 473

Metastatic Melanoma-Discontinued Products 483

Metastatic Melanoma-Product Development Milestones 484

Featured News & Press Releases 484

Appendix 492

Methodology 492

Coverage 492

Secondary Research 492

Primary Research 492

Expert Panel Validation 492

Contact Us 492

Disclaimer 493

List of Tables

Number of Products under Development for Metastatic Melanoma, H1 2015 22

Number of Products under Development for Metastatic Melanoma-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 25

Number of Products under Development by Companies, H1 2015 (Contd..1) 26

Number of Products under Development by Companies, H1 2015 (Contd..2) 27

Number of Products under Development by Companies, H1 2015 (Contd..3) 28

Number of Products under Development by Companies, H1 2015 (Contd..4) 29

Number of Products under Development by Companies, H1 2015 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Development, H1 2015 35

Products under Development by Companies, H1 2015 36

Products under Development by Companies, H1 2015 (Contd..1) 37

Products under Development by Companies, H1 2015 (Contd..2) 38

Products under Development by Companies, H1 2015 (Contd..3) 39

Products under Development by Companies, H1 2015 (Contd..4) 40

Products under Development by Companies, H1 2015 (Contd..5) 41

Products under Development by Companies, H1 2015 (Contd..6) 42

Products under Development by Companies, H1 2015 (Contd..7) 43

Products under Investigation by Universities/Institutes, H1 2015 44

Metastatic Melanoma-Pipeline by AB Science, H1 2015 45

Metastatic Melanoma-Pipeline by AbbVie Inc., H1 2015 46

Metastatic Melanoma-Pipeline by Adaptimmune Limited, H1 2015 47

Metastatic Melanoma-Pipeline by Affichem, H1 2015 48

Metastatic Melanoma-Pipeline by Agalimmune Ltd, H1 2015 49

Metastatic Melanoma-Pipeline by Agenus, Inc., H1 2015 50

Metastatic Melanoma-Pipeline by Altor BioScience Corporation, H1 2015 51

Metastatic Melanoma-Pipeline by Amgen Inc., H1 2015 52

Metastatic Melanoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 53

Metastatic Melanoma-Pipeline by AstraZeneca PLC, H1 2015 54

Metastatic Melanoma-Pipeline by AVAX Technologies, Inc., H1 2015 55

Metastatic Melanoma-Pipeline by Bayer AG, H1 2015 56

Metastatic Melanoma-Pipeline by Bioncotech Therapeutics S.L., H1 2015 57

Metastatic Melanoma-Pipeline by Bionomics Limited, H1 2015 58

Metastatic Melanoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 59

Metastatic Melanoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 60

Metastatic Melanoma-Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 61

Metastatic Melanoma-Pipeline by Cavion LLC, H1 2015 62

Metastatic Melanoma-Pipeline by Celgene Corporation, H1 2015 63

Metastatic Melanoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 64

Metastatic Melanoma-Pipeline by Colby Pharmaceutical Company, H1 2015 65

Metastatic Melanoma-Pipeline by CureTech Ltd., H1 2015 66

Metastatic Melanoma-Pipeline by Delcath Systems, Inc., H1 2015 67

Metastatic Melanoma-Pipeline by Digna Biotech, S.L., H1 2015 68

Metastatic Melanoma-Pipeline by DNA Therapeutics S.A., H1 2015 69

Metastatic Melanoma-Pipeline by Eisai Co., Ltd., H1 2015 70

Metastatic Melanoma-Pipeline by Eli Lilly and Company, H1 2015 71

Metastatic Melanoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 72

Metastatic Melanoma-Pipeline by Galapagos NV, H1 2015 73

Metastatic Melanoma-Pipeline by Galectin Therapeutics, Inc., H1 2015 74

Metastatic Melanoma-Pipeline by GlaxoSmithKline plc, H1 2015 75

Metastatic Melanoma-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 76

Metastatic Melanoma-Pipeline by Immune Design Corp., H1 2015 77

Metastatic Melanoma-Pipeline by Immunophotonics Inc, H1 2015 78

Metastatic Melanoma-Pipeline by ImmuRx, Inc., H1 2015 79

Metastatic Melanoma-Pipeline by Incyte Corporation, H1 2015 80

Metastatic Melanoma-Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2015 81

Metastatic Melanoma-Pipeline by Lipotek Pty Ltd., H1 2015 82

Metastatic Melanoma-Pipeline by Luitpold Pharmaceuticals, Inc., H1 2015 83

Metastatic Melanoma-Pipeline by MedImmune, LLC, H1 2015 84

Metastatic Melanoma-Pipeline by Merck & Co., Inc., H1 2015 85

Metastatic Melanoma-Pipeline by Merck KGaA, H1 2015 86

Metastatic Melanoma-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 87

Metastatic Melanoma-Pipeline by Morphotek, Inc., H1 2015 88

Metastatic Melanoma-Pipeline by NeoStem, Inc., H1 2015 89

Metastatic Melanoma-Pipeline by NewLink Genetics Corporation, H1 2015 90

Metastatic Melanoma-Pipeline by Novartis AG, H1 2015 91

Metastatic Melanoma-Pipeline by Omeros Corporation, H1 2015 92

Metastatic Melanoma-Pipeline by Oncolytics Biotech Inc., H1 2015 93

Metastatic Melanoma-Pipeline by OncoSec Medical Inc., H1 2015 94

Metastatic Melanoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 95

Metastatic Melanoma-Pipeline by Onxeo SA, H1 2015 96

Metastatic Melanoma-Pipeline by Pfizer Inc., H1 2015 97

Metastatic Melanoma-Pipeline by Philogen S.p.A., H1 2015 98

Metastatic Melanoma-Pipeline by Plexxikon Inc., H1 2015 99

Metastatic Melanoma-Pipeline by Polyphor Ltd., H1 2015 100

Metastatic Melanoma-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 101

Metastatic Melanoma-Pipeline by Provenance Biopharmaceuticals Corp., H1 2015 102

Metastatic Melanoma-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 103

Metastatic Melanoma-Pipeline by Recombio S.L, H1 2015 104

Metastatic Melanoma-Pipeline by Sanofi, H1 2015 105

Metastatic Melanoma-Pipeline by SBI Biotech Co., Ltd., H1 2015 106

Metastatic Melanoma-Pipeline by Scancell Holdings Plc, H1 2015 107

Metastatic Melanoma-Pipeline by Takara Bio Inc., H1 2015 108

Metastatic Melanoma-Pipeline by Takeda Oncology, H1 2015 109

Metastatic Melanoma-Pipeline by Ultimovacs AS, H1 2015 110

Metastatic Melanoma-Pipeline by Vaxeal Holding SA, H1 2015 111

Metastatic Melanoma-Pipeline by Vical Incorporated, H1 2015 112

Metastatic Melanoma-Pipeline by WntResearch AB, H1 2015 113

Metastatic Melanoma-Pipeline by ZIOPHARM Oncology, Inc., H1 2015 114

Assessment by Monotherapy Products, H1 2015 115

Assessment by Combination Products, H1 2015 116

Number of Products by Stage and Target, H1 2015 118

Number of Products by Stage and Mechanism of Action, H1 2015 125

Number of Products by Stage and Route of Administration, H1 2015 130

Number of Products by Stage and Molecule Type, H1 2015 132

Metastatic Melanoma Therapeutics-Recent Pipeline Updates, H1 2015 360

Metastatic Melanoma-Dormant Projects, H1 2015 482

Metastatic Melanoma-Dormant Projects (Contd..1), H1 2015 483

Metastatic Melanoma-Dormant Projects (Contd..2), H1 2015 484

Metastatic Melanoma-Dormant Projects (Contd..3), H1 2015 485

Metastatic Melanoma-Dormant Projects (Contd..4), H1 2015 486

Metastatic Melanoma-Dormant Projects (Contd..5), H1 2015 487

Metastatic Melanoma-Dormant Projects (Contd..6), H1 2015 488

Metastatic Melanoma-Dormant Projects (Contd..7), H1 2015 489

Metastatic Melanoma-Dormant Projects (Contd..8), H1 2015 490

Metastatic Melanoma-Dormant Projects (Contd..9), H1 2015 491

Metastatic Melanoma-Discontinued Products, H1 2015 492

List of Figures

Number of Products under Development for Metastatic Melanoma, H1 2015 22

Number of Products under Development for Metastatic Melanoma-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 24

Number of Products under Investigation by Universities/Institutes, H1 2015 31

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Products, H1 2015 35

Assessment by Monotherapy Products, H1 2015 115

Assessment by Combination Products, H1 2015 116

Number of Products by Top 10 Targets, H1 2015 117

Number of Products by Stage and Top 10 Targets, H1 2015 117

Number of Products by Top 10 Mechanism of Actions, H1 2015 124

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 124

Number of Products by Top 10 Routes of Administration, H1 2015 129

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 129

Number of Products by Top 10 Molecule Types, H1 2015 131

Number of Products by Stage and Top 10 Molecule Types, H1 2015 131

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

Adaptimmune Limited

Affichem

Agalimmune Ltd

Agenus, Inc.

Altor BioScience Corporation

Amgen Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

AVAX Technologies, Inc.

Bayer AG

Bioncotech Therapeutics S.L.

Bionomics Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cancer Therapeutics CRC Pty Ltd

Cavion LLC

Celgene Corporation

Celldex Therapeutics, Inc.

Colby Pharmaceutical Company

CureTech Ltd.

Delcath Systems, Inc.

Digna Biotech, S.L.

DNA Therapeutics S.A.

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Galapagos NV

Galectin Therapeutics, Inc.

GlaxoSmithKline plc

HanAll Biopharma Co., Ltd.

Immune Design Corp.

Immunophotonics Inc

ImmuRx, Inc.

Incyte Corporation

Life Science Pharmaceuticals, Incorporated

Lipotek Pty Ltd.

Luitpold Pharmaceuticals, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Momenta Pharmaceuticals, Inc.

Morphotek, Inc.

NeoStem, Inc.

NewLink Genetics Corporation

Novartis AG

Omeros Corporation

Oncolytics Biotech Inc.

OncoSec Medical Inc.

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Pfizer Inc.

Philogen S.p.A.

Plexxikon Inc.

Polyphor Ltd.

Provectus Biopharmaceuticals, Inc.

Provenance Biopharmaceuticals Corp.

Reata Pharmaceuticals, Inc.

Recombio S.L

Sanofi

SBI Biotech Co., Ltd.

Scancell Holdings Plc

Takara Bio Inc.

Takeda Oncology

Ultimovacs AS

Vaxeal Holding SA

Vical Incorporated

WntResearch AB

ZIOPHARM Oncology, Inc.

Metastatic Melanoma Therapeutic Products under Development, Key Players in Metastatic Melanoma Therapeutics, Metastatic Melanoma Pipeline Overview, Metastatic Melanoma Pipeline, Metastatic Melanoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com